GSTZ1 and peripheral neuropathy: The most prevalent and serious side effect associated with DCA is reversible peripheral neuropathy.[13] DCA metabolism is influenced by age and GSTZ1 genotype; therefore, in addition to age considerations in long-term DCA administration, adjusted DCA dosage according to GSTZ1 haplotype may be a possible way to ameliorate peripheral neurotoxicity.